Skip to content

Brian E Krumm

3 papers in the library · 268 citations · publishing 2022-2025

Papers

Sort Most recent Most cited

The structural diversity of psychedelic drug actions revealed.

Nat Commun March 19, 2025 Ryan H. Gumpper, Manish K. Jain, Kuglae Kim et al. 31 citations

There is currently a resurgence in exploring the utility of classical psychedelics to treat depression, addiction, anxiety disorders, cluster headaches, and many other neuropsychiatric disorders. A biological target of these compounds, and a hypothesized target for their therapeutic actions, is the 5-HT2A serotonin receptor. Here, we present 7 cryo-EM structures covering all major compound...

Ligand and G-protein selectivity in the κ-opioid receptor.

Nature May 1, 2023 Jianming Han, Jingying Zhang, Antonina L. Nazarova et al. 79 citations

The κ-opioid receptor (KOR) represents a highly desirable therapeutic target for treating not only pain but also addiction and affective disorders1. However, the development of KOR analgesics has been hindered by the associated hallucinogenic side effects2. The initiation of KOR signalling requires the Gi/o-family proteins including the conventional (Gi1, Gi2, Gi3, GoA and GoB) and...

Signaling snapshots of a serotonin receptor activated by the prototypical psychedelic LSD.

Neuron October 5, 2022 Can Cao, Ximena Barros-Álvarez, Shicheng Zhang et al. 158 citations

Serotonin (5-hydroxytryptamine [5-HT]) 5-HT2-family receptors represent essential targets for lysergic acid diethylamide (LSD) and all other psychedelic drugs. Although the primary psychedelic drug effects are mediated by the 5-HT2A serotonin receptor (HTR2A), the 5-HT2B serotonin receptor (HTR2B) has been used as a model receptor to study the activation mechanisms of psychedelic drugs due to...